Invitrogen and Greiner Bio-One tackle HPV

Invitrogen and Greiner Bio-One are to collaborate to reduce the number of false positive diagnoses of human papilloma virus (HPV), it has been revealed.

A strategic partnership between the two firms is to see a procedure patented by Invitrogen used to reduce contamination between samples studied by Greiner Bio-One’s PapilloCheck and CytoCheck products.

In this way, it is hoped that the number of false positives achieved could be significantly lowered.

Amy Butler, Invitrogen vice president of gene expression profiling, said: "Greiner Bio-One’s HPV test will now deliver more reliable results for women who may need to be treated for HPV, which is the leading cause of cervical cancer."

"Licensing patented technologies like 2-deoxyuridine 5-triphosphate is allowing Invitrogen to assist diagnostic companies around the world," she added.

Greiner Bio-One claims that cervical cancer which is caught in the early stages is cured in almost 100 per cent of cases.